WINTON GROUP Ltd Invests $6.04 Million in Illumina, Inc. $ILMN

Posted by Stanley Muller on Sep 11th, 2026

WINTON GROUP Ltd bought a new position in shares of Illumina, Inc. (NASDAQ:ILMN – Free Report) in the 2nd quarter, Holdings Channel.com reports. The institutional investor bought 34,357 shares of the life sciences company’s stock, valued at approximately $6,041,000.

Several other institutional investors have also bought and sold shares of the stock. Fiduciary Financial Advisors bought a new stake in Illumina in the second quarter valued at $26,000. Keating Financial Advisory Services Inc. bought a new position in shares of Illumina during the second quarter valued at $32,000. Rakuten Securities Inc. bought a new position in shares of Illumina during the second quarter valued at $33,000. Elyxium Wealth LLC acquired a new stake in shares of Illumina in the 4th quarter valued at $25,000. Finally, Elevation Wealth Partners LLC boosted its stake in shares of Illumina by 52.5% in the 2nd quarter. Elevation Wealth Partners LLC now owns 244 shares of the life sciences company’s stock valued at $43,000 after purchasing an additional 84 shares in the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Illumina Price Performance

Shares of ILMN stock opened at $201.27 on Friday. Illumina, Inc. has a 52-week low of $88.00 and a 52-week high of $231.81. The stock has a market cap of $30.39 billion, a PE ratio of 37.55, a PEG ratio of 2.90 and a beta of 1.46. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.40 and a current ratio of 1.80. The firm’s 50 day moving average price is $200.54 and its two-hundred day moving average price is $161.87.

Illumina (NASDAQ:ILMN – Get Free Report) last released its quarterly earnings data on Thursday, July 30th. The life sciences company reported $1.31 EPS for the quarter, beating analysts’ consensus estimates of $1.23 by $0.08. The business had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.13 billion. Illumina had a return on equity of 29.84% and a net margin of 18.36%.The firm’s revenue was up 9.4% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.19 earnings per share. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, analysts forecast that Illumina, Inc. will post 5.36 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on the stock. Wall Street Zen upgraded shares of Illumina from a “hold” rating to a “buy” rating in a research report on Saturday, August 1st. Citigroup boosted their price target on shares of Illumina from $95.00 to $113.00 and gave the company a “sell” rating in a research report on Monday, August 3rd. Argus upped their price objective on shares of Illumina from $180.00 to $235.00 and gave the stock a “buy” rating in a research note on Thursday, September 3rd. Guggenheim raised their price objective on shares of Illumina from $200.00 to $226.00 and gave the stock a “buy” rating in a report on Friday, July 31st. Finally, Barclays lifted their target price on shares of Illumina from $145.00 to $160.00 and gave the company an “underweight” rating in a research note on Friday, July 31st. Ten investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $199.12.

Check Out Our Latest Research Report on Illumina

Insider Transactions at Illumina

In other Illumina news, Director Keith Meister sold 457,858 shares of the company’s stock in a transaction that occurred on Tuesday, August 4th. The shares were sold at an average price of $200.10, for a total value of $91,617,385.80. Following the completion of the sale, the director owned 2,372,694 shares of the company’s stock, valued at approximately $474,776,069.40. This represents a 16.18% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold a total of 2,062,465 shares of company stock worth $436,589,802 in the last ninety days. 2.90% of the stock is currently owned by insiders.

Illumina Profile

(Free Report)

Illumina, Inc develops and manufactures genomic analysis technologies used by researchers, healthcare providers, pharmaceutical companies and other organizations. Its offerings include next-generation DNA sequencing systems, microarray platforms, consumables, laboratory services and bioinformatics software designed to help analyze genetic variation and biological functions.

The company’s sequencing instruments include systems for a range of applications and throughput levels, such as the NovaSeq, NextSeq, MiSeq and iSeq platforms.